Status:
COMPLETED
Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Lead Sponsor:
Santen SAS
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Evaluation of safety and tolerability of a single injection of NOVA63035 "Corticosteroid" administered at one of four doses in patients with diabetic macular edema (DME) secondary to diabetic retinopa...
Eligibility Criteria
Inclusion
- M \& F 18 years and older
- Diagnosed with diabetes mellitus and presenting diabetic retinopathy
Exclusion
- Monocular
- History of current ocular hypertension or glaucoma in either eye defined
- Any significant ocular disease (other than diabetic retinopathy)
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00665106
Start Date
April 1 2008
End Date
September 1 2011
Last Update
May 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Midwest Eye Institute
Indianapolis, Indiana, United States, 46280